article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Smith states, weve definitely come across people in the pharma industry who worry that AI means companies might steal our data or use it in harmful ways. As the industry gains more exposure to AIs real-world applications and the rigorous standards AI companies adhere to, trust will continue to grow.

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection.

article thumbnail

ICH E6(R3) Implementation Starts Now: Are You Ready?

Advarra

What Pharma Sponsors Are Asking As sponsors prepare for ICH E6(R3), a few common questions have emerged: Where do we start? Many pharma companies are unsure how to begin aligning with the new expectations, especially around trial design and quality systems.

article thumbnail

US sees 185% jump in tenant demand for biomanufacturing space, as lab leasing craters

Pharma Manufacturing

While Big Pharma companies have announced $270 billion in domestic investments, lab leasing declined significantly in Q1 2025, finds JLL’s U.S. Life Sciences Property Report.

article thumbnail

The Current State of Biotransformation Science 2024

Metabolite Tales Blog

The paper gives a useful insight into the most commonly used in vitro MetID practices across 26 pharma companies, and crucially reveals how effective these systems are at predicting circulating human metabolites. Hypha’s clients range from small through to large pharma companies.

article thumbnail

Valuation of Pharma Companies: 5 Key Considerations

Drug Patent Watch

"5 Key Considerations for Valuing Pharma Companies As the pharmaceutical industry continues to evolve, accurately valuing pharma companies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.